Wilson Salgado Júnior1, Carlos Augusto de Mattos Donadelli2, José Sebastião Dos Santos2, Carla Barbosa Nonino3. 1. Department of Surgery and Anatomy, Clinical Hospital, Faculty of Medicine, University of São Paulo, Ribeirão Preto, São Paulo, Brazil. wsalgado@fmrp.usp.br. 2. Department of Surgery and Anatomy, Clinical Hospital, Faculty of Medicine, University of São Paulo, Ribeirão Preto, São Paulo, Brazil. 3. Nutritional Division of the Department of Medical Clinic, Clinical Hospital, Faculty of Medicine, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
Abstract
BACKGROUND: Obesity is associated with nonalcoholic fatty liver disease (NAFLD), which is improved by bariatric surgery. Hepatobiliary scintigraphy with 99m.-Tc diisopropylacetanilido iminodiacetic acid (99mTc-DISIDA) has proved to be highly effective for the assessment of bile flow, representing an indirect measurement of hepatocyte and cholangiocyte function. The objective of this study was to assess the effects of Roux-en-Y gastric bypass (RYGB) on bile flow in obese subjects by hepatobiliary scintigraphy. This study was conducted in a public university hospital in Brazil. METHODS: Twenty obese patients and five nonobese patients (with no hepatic or biliary disease) were studied. The obese patients were submitted to anthropometric evaluation and biochemical exams when they arrived at the service, during the immediate preoperative period and 3, 6, and 12 months after surgery. They were also submitted to abdominal ultrasound and hepatobiliary scintigraphy with 99mTc-DISIDA during the preoperative period and 12 months after RYGB. Tmax (time of maximum marker uptake) and T1/2 (half time between peak uptake and disappearance of the marker) were determined and compared between obese patients and controls, before and after surgery. The results were compared to those obtained with an intraoperative liver biopsy. RESULTS: A weight loss of 12.2 ± 4.3 % was observed during preparation for surgery, and a loss of 30.4 ± 5.6 % was observed 1 year after RYGB. Ultrasound hepatic analysis revealed some degree of NAFLD in the operated patients. Obese patients showed a prolonged T1/2 compared to control, with a reduction to normal levels after RYGB. CONCLUSIONS: We concluded that NAFLD compromises bile excretion, a process that can be reversed by treatment with RYGB.
BACKGROUND: Obesity is associated with nonalcoholic fatty liver disease (NAFLD), which is improved by bariatric surgery. Hepatobiliary scintigraphy with 99m.-Tc diisopropylacetanilido iminodiacetic acid (99mTc-DISIDA) has proved to be highly effective for the assessment of bile flow, representing an indirect measurement of hepatocyte and cholangiocyte function. The objective of this study was to assess the effects of Roux-en-Y gastric bypass (RYGB) on bile flow in obese subjects by hepatobiliary scintigraphy. This study was conducted in a public university hospital in Brazil. METHODS: Twenty obesepatients and five nonobese patients (with no hepatic or biliary disease) were studied. The obesepatients were submitted to anthropometric evaluation and biochemical exams when they arrived at the service, during the immediate preoperative period and 3, 6, and 12 months after surgery. They were also submitted to abdominal ultrasound and hepatobiliary scintigraphy with 99mTc-DISIDA during the preoperative period and 12 months after RYGB. Tmax (time of maximum marker uptake) and T1/2 (half time between peak uptake and disappearance of the marker) were determined and compared between obesepatients and controls, before and after surgery. The results were compared to those obtained with an intraoperative liver biopsy. RESULTS: A weight loss of 12.2 ± 4.3 % was observed during preparation for surgery, and a loss of 30.4 ± 5.6 % was observed 1 year after RYGB. Ultrasound hepatic analysis revealed some degree of NAFLD in the operated patients. Obesepatients showed a prolonged T1/2 compared to control, with a reduction to normal levels after RYGB. CONCLUSIONS: We concluded that NAFLD compromises bile excretion, a process that can be reversed by treatment with RYGB.
Authors: Carlos K Furuya; Claudia P M S de Oliveira; Evandro S de Mello; Joel Faintuch; Alessandra Raskovski; Mitsunori Matsuda; Denise C P Vezozzo; Alfredo Halpern; Arthur B Garrido; Venâncio A F Alves; Flair J Carrilho Journal: J Gastroenterol Hepatol Date: 2007-04 Impact factor: 4.029
Authors: David E Kleiner; Elizabeth M Brunt; Mark Van Natta; Cynthia Behling; Melissa J Contos; Oscar W Cummings; Linda D Ferrell; Yao-Chang Liu; Michael S Torbenson; Aynur Unalp-Arida; Matthew Yeh; Arthur J McCullough; Arun J Sanyal Journal: Hepatology Date: 2005-06 Impact factor: 17.425
Authors: Miller Barreto de Brito E Silva; Francisco Tustumi; Antonio Afonso de Miranda Neto; Anna Carolina Batista Dantas; Marco Aurélio Santo; Ivan Cecconello Journal: Obes Surg Date: 2021-04-13 Impact factor: 4.129